Skip to main content
Premium Trial:

Request an Annual Quote

BD Completes Accuri Cytometers Buy

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today announced the completion of its acquisition of Accuri Cytometers for an undisclosed amount.

Based in Ann Arbor, Mich., Accuri develops personal flow cytometers. The acquisition, announced last month during BD's first quarter earnings release, helps expand the use of flow cytometry technology in regions where ease of use and affordability are critical, BD said.

"The acquisition … complements and broadens BD's offerings for life scientists by making flow cytometry more accessible to a wider audience of scientists and clinicians," William Rhodes, president of BD Biosciences, said in a statement.